Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - INTERPACE BIOSCIENCES, INC.ex99-1.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

   


 FORM 8-K 

 


CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 29, 2017


   

Interpace Diagnostics Group, Inc.

(Exact name of registrant as specified in its charter) 

   


Delaware

 

000-24249

 

22-2919486

(State or other jurisdiction of

incorporation)

 

(Commission File Number)

 

(IRS Employer Identification No.)

  

Morris Corporate Center 1, Building A

300 Interpace Parkway

Parsippany, NJ 07054

(Address, including zip code, of Principal Executive Offices)

 

(855) 776-6419

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

 

Item 2.02     Results of Operations and Financial Condition.

 

On March 29, 2017, Interpace Diagnostics Group, Inc. issued a press release announcing its results of operations and financial condition for the fiscal year ended December 31, 2016. The full text of the press release is set forth as Exhibit 99.1 attached hereto and is incorporated herein by reference.

 

The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.

 

 

Item 9.01.     Financial Statements and Exhibits

 

(d)     Exhibits

 

Exhibit

Number

Description

 

 

99.1

Press Release dated March 29, 2017

 

 
 

 

 

signatureS

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 Interpace Diagnostics Group, Inc.

 

 

 

 

 

 

 

 

 

Date: March 29, 2017

By:

/s/ Jack E. Stover

 

 

Name:

 Jack E. Stover

 

 

Title:

 President and Chief Executive Officer

 

 

 
 

 

 

EXHIBIT INDEX

  

Exhibit

Number

Description

 

 

99.1

Press Release dated March 29, 2017